SBIR Phase I: Development of Soluble Analyte Amplification for PBP2a Detection

SBIR 第一阶段：开发用于 PBP2a 检测的可溶性分析物扩增

• 批准号: 0945155
• 负责人: Robert Lawton
• 金额: --
• 依托单位: New England Rare Reagents
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-01-01 至 2010-12-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0945155&HistoricalAwards=false
• 关键词: SBIR; Phase; Development; Soluble; Analyte

This Small Business Innovation Research (SBIR) Phase I project is to develop a prototype feasibility assay for low level detection of methacillin resistant Staphlococcus aureus (MRSA) protein biomarker, Penicillin Binding Protein 2a (PBP2a), using an innovative, patented detection technology. The company has developed a detection technology called Soluble Analyte Amplification, or SAM, a versatile diagnostic platform that is capable of identifying biological molecules at currently undetectable concentrations in solution. In the US over 94,000 patients acquire MRSA bloodstream infection yearly with a mortality rate of almost 20%. Currently, no diagnostic platforms can detect MRSA directly from blood. The project will use the SAM technology to develop an assay that will detect PBP2A in blood.The broader impacts of this research are the development of the innovative SAM technology that will serve as a springboard from which SAM will find multiple applications in human medicine. While clinical diagnostic testing has profoundly impacted healthcare delivery, the sensitivity of tests currently on the market do not have the ability to detect molecules at the low levels observed early in disease when treatment is more efficacious. Introduction of a SAM-based assay system as a sensitive and easy to use technology for detection of proteins, carbohydrates and other molecules of interest at very low concentration will enhance the understanding of many diseases and lead to important advances in therapeutics and early detection strategies.

这个小型企业创新研究(SBIR)第一阶段项目是利用一种创新的专利检测技术，开发一种原型可行性分析，用于低水平检测耐甲氧西林金黄色葡萄球菌(MRSA)蛋白生物标记物青霉素结合蛋白2a(PBP2a)。该公司开发了一种名为可溶性分析放大或SAM的检测技术，这是一个多功能诊断平台，能够在目前无法检测到的溶液浓度下识别生物分子。在美国，每年有超过94,000名患者患上MRSA血流感染，死亡率接近20%。目前，还没有诊断平台可以直接从血液中检测到MRSA。该项目将使用SAM技术开发一种检测血液中PBP2a的分析方法。这项研究的更广泛影响是开发创新的SAM技术，这将成为SAM在人类医学中找到多种应用的跳板。虽然临床诊断检测对医疗保健服务产生了深远的影响，但目前市场上的检测灵敏度无法在治疗更有效的疾病早期观察到的低水平检测到分子。引进基于SAM的分析系统，作为一种灵敏和易于使用的技术，在极低浓度下检测蛋白质、碳水化合物和其他感兴趣的分子，将加强对许多疾病的了解，并导致治疗学和早期检测策略的重要进展。